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importance of this symptomatic shedding in
transmission among preschool children is well
established (3); however, that of symptom-free
shedding in adults is unknown. We report here
that the rate of symptom-free STEC O157:H7
shedding is higher in adults 30 to 49 years of age
than in others.
STEC infections have been notifiable in
Japan since August 1996. When STEC is found
in the feces of patients in schools, families, and
hospitals, local health centers and public health
institutes must test (generally using MacConkey
sorbitol agar with cefixime-potassium tellurite
medium) for the pathogen in stool specimens of
contacts of the patients. The pathogen is also
sought twice a month in the stool specimens of
food-handlers. All isolates from culture-positive
patients are collected by Japans National
Institute of Infectious Diseases.
In 1997, 1,412 STEC O157:H7 human
isolates were examined  for subtyping of Shiga
toxin genes stx1 and stx2 by polymerase chain
reaction, for genotyping by XbaI-digested
pulsed-field gel electrophoresis (PFGE) (4,5),
and for their relationship with symptoms; 1,381
isolates (from culture-positive persons with well-
characterized clinical status) were further
analyzed. The rates by age group among STEC
O157:H7-shedding persons reporting one or
more symptoms (vs. culture-positive persons
without symptoms) were as follows: 82% (475 of
576) younger than 10 years old; 81% (145 of 178),
10 to 19 years; 63% (98 of 156), 20 to 29 years;
25% (32 of 128), 30 to 39 years; 34% (34 of 100), 40
to 49 years; 54% (57 of 106), 50 to 59 years; 56%
(38 of 68), 60 to 69 years; 68% (47 of 69), older
than 70 years. Culture-positive persons under 20
years of age, especially children under 10 years
of age, were more likely to have symptoms than
other age groups. Intermediate rates of
symptom-free persons with positive stool
cultures occurred in young adults (20 to 29 years
of age) and the elderly (70 years of age), while the
highest rates of stool-positive, symptom-free
persons were adults, especially those between 30
and 49 years of age. In terms of pathogen
virulence, we did not find significant differences
in the distribution of stx subtypes and PFGE
genotypes between strains shed by symptomatic
and asymptomatic persons. These results
suggest that the rate of symptom-free STEC
O157:H7 shedding may be associated with age
rather than organism-related factors. Possible
age-related host factors that could influence the
presence of STEC O157:H7 in the stools of
symptom-free persons include qualitative and
quantitative differences in intestinal cross-
reactive antibodies against STEC O157:H7,
intestinal bacterial flora, or the sensitivity to Stx
toxins between children and adults. Further
investigations will be required to determine the
relative importance of these and other host
factors. Our finding of a high rate of
asymptomatic shedding in adults may suggest
the  potential for secondary transmission of the
bacteria from symptom-free STEC O157:H7-
shedding adults to healthy children.
Acknowledgments
We thank investigators of prefectural and municipal
public health institutes for their collaboration.
This work was supported by a grant from the Ministry of
Health and Welfare of Japan.
Jun Terajima, Hidemasa Izumiya,
Akihito Wada, Kazumichi Tamura, and
Haruo Watanabe
National Institute of Infectious Diseases,
Tokyo, Japan
References
  1. Tarr PI. Escherichia coli O157:H7: clinical, diagnostic,
and epidemiological aspects of human infection. Clin
Infect Dis 1995;20:1-8.
  2. Belongia EA, Osterholm MT, Soler JT, Ammend DA,
Braun JE, MacDonald KL. Transmission of Escherichia
coli O157:H7 infection in Minnesota child day-care
facilities. JAMA 1993;269:883-8.
    3. Karch H, Russman H, Schmidt H, Schwarzkopf A,
Heesmann J. Long-term shedding and clonal turnover
of enterohemorrhagic Escherichia coli O157:H7 in
diarrheal diseases. J Clin Microbiol 1995;33:1602-5.
  4. Watanabe H, Wada A, Inagaki Y, Itoh K, Tamura K.
Outbreaks of enterohaemorrhagic Escherichia coli
O157:H7 infection by two different genotype strains in
Japan. Lancet 1996;348:831-2.
  5. Izumiya H, Terajima J, Wada A, Inagaki Y, Itoh K,
Tamura K,  et al. Molecular typing of enterohemorrhagic
Escherichia coli O157:H7 isolates in Japan by using
pulsed-field gel electrophoresis. J Clin Microbiol
1997;35:1675-80.
Streptococcus pyogenes Erythromycin
Resistance in Italy
To the Editor: Streptococcus pyogenes resistance
to erythromycin began to emerge as a serious
problem worldwide in the early 1990s. In some
areas in Italy, 30% to 40% of strains have beome303 Vol. 5, No. 2, MarchApril 1999 Emerging Infectious Diseases
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resistant (1-3). Throughout Italy, the use of
macrolides, particularly the newest ones
(azithromycin and clarithromycin), has in-
creased in the treatment of infections caused by
Group A streptococci. This therapeutic approach
is contrary to current guidelines, which
recommend using betalactam antibiotics as first-
choice therapy and reserving macrolides only for
patients allergic to betalactams.
In 1997 in Finland, a decrease was observed
in the use of macrolide antibiotics in ambulatory
patients from 2.40 defined daily doses per 1,000
inhabitants in 1991 to 1.38 in 1992. Subse-
quently, the maintenance of doses at 1.28 to 1.74
defined daily doses resulted in a substantial
decrease in the percentage of group A
streptococcal resistance to erythromycin, re-
ported as 16.5% in 1992, 19% in 1993, 15.6% in
1994, 10% in 1995, and 8.6% in 1996 (4). These
data prompted us to evaluate such phenomena in
our geographic area, the urban area of Genoa,
Italy (approximately 120,000 inhabitants).
From January 1991 to June 1998, 311 (6.1%)
of 5,117 strains of S. pyogenes throat swabs from
patients with pharyngotonsillitis were isolated.
We observed a higher number of group A
streptococci isolates from throat swabs starting
in 1996 than we had in 1991 to 1995 (chi-square
= 35.653, p <0.0001). All isolates were tested for
susceptibility to penicillin and erythromycin by
standard susceptibility tests (broth microdilution)
as recommended by the National Committee for
Clinical Laboratory Standards. All isolates were
susceptible to penicillin. From 1991 to 1996, the
percentage of S. pyogenes resistant or with
intermediate resistance to erythromycin
increased from 0% to 50% (1992, 6%; 1993, 13%;
1994, 14%; 1995, 24%; 1996, 50%). In 1997 and
the first half of 1998, resistance to erythromycin
decreased to 39% and 34%, respectively. The
number of resistant strains before 1996 was
significantly lower than from 1996 to 1998 (chi-
square = 50.386, p <0.0001). Analysis of
antibiotic consumption in our district showed an
increase in the use of macrolides (erythromycin
and the new compounds clarithromycin and
azithromycin) from 0.445 defined daily dose per
1,000 inhabitants in 1994 to 1.140 in 1996. In
1997 and in the first half of 1998, consumption
decreased to 0.9 and 0.8, respectively; we
observed a correlation between the number of
resistant isolates and the defined daily dose
increase (correlation [R2] = 0.795, p = 0.0153).
S. pyogenes resistance to erythromycin rose
from 6% to 50% in only 4 years and then rapidly
decreased from 50% to 34% in an 18-month
period, corresponding to a 57% decrease in
defined daily dose (from 1.41 in 1996 to 0.8 in the
first half of 1998). Our data suggest that
S. pyogenes resistance to erythromycin is
associated with frequency of macrolide use.
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Estimated Incidence of Clostridium
difficile Infection
To the Editor: Since the publication of our article
Increasing hospitalization and death, possibly
due to Clostridium difficile diarrheal disease (1),
we have received several requests to estimate
the incidence of C. difficile infection. Our
original study included only hospitalized
patients treated at the Lovelace Medical Center
from 1993 to 1996, and no information on the
incidence of C. difficile infection. In response to
these requests, we used inpatient and outpatient
medical claims for the Lovelace managed care
population to calculate incidence rates. We
searched medical claims for the Lovelace Health
Plan/Senior Plan (LHP) to identify patients who
had a C. difficile diagnosis between January 1,
1993, and December 31, 1997. LHP members are
residents of New Mexico, most residing in or near
Albuquerque.